Intranasal Delivery of Ligand‐Conjugated NLCs Co‐Loaded With Docetaxel and Quercetin: HPLC Method Development, Pharmacokinetics, and Brain Biodistribution in Wistar Rats for Glioblastoma
Biomedical Chromatography · 2026
DOI: 10.1002/bmc.70251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2026. Verfasst von Zufika Qamar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. Hauptthemen laut MEDLINE: Quercetin, Docetaxel, Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 78 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research (CSIR), India.
Abstract (Originalsprache)
Glioblastoma multiforme (GB) is the most aggressive type of brain cancer, with treatment hindered by ineffective drug delivery across the blood–brain barrier and systemic side effects. Nanostructured lipid carriers (NLCs) are innovative nanocarriers that can improve drug solubility, stability, and targeted delivery to the brain. (DX–QR) NLC was developed and optimized using a modified emulsification‐sonication method and a central composite rotatable design. Surface conjugation of (DX–QR) NLC with transferrin (Tf) was achieved through carbodiimide chemistry resulting in the formulation of Tf‐(DX–QR) NLC. A high‐performance liquid chromatography (HPLC) method was established and validated according to ICH Q2(R1) standards for simultaneous measurement of docetaxel (DX) and quercetin (QR) in plasma, brain tissue, and other organs of Wistar rats. Using a Shim‐pack Solar C18 column and an acetonitrile‐water (60:40) mobile phase at a 242 nm wavelength, the method demonstrated linearity ( R 2 > 0.9900), along with accuracy, precision, and recovery rates > 98%. The developed method was used to evaluate the pharmacokinetics and biodistribution of DX and QR, indicating that intranasal (IN) administration of Tf‐(DX–QR) NLC resulted in brain concentrations of DX (4.6‐fold) and QR (8.8‐fold) higher than those achieved through (DX–QR) suspension delivered via intravenous (IV) and IN, highlighting their potential as noninvasive, effective, and targeted treatments for GB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
Förderung
- Council of Scientific and Industrial Research (CSIR), India
Zitieren
APA
Qamar, Z., Khan, S. A., Haider, F., Moonis, M., Ali, J., Baboota, S., & Ali, A. (2026). Intranasal Delivery of Ligand‐Conjugated NLCs Co‐Loaded With Docetaxel and Quercetin: HPLC Method Development, Pharmacokinetics, and Brain Biodistribution in Wistar Rats for Glioblastoma. Biomedical Chromatography. https://doi.org/10.1002/bmc.70251
Vancouver
Qamar Z, Khan SA, Haider F, Moonis M, Ali J, Baboota S, et al. Intranasal Delivery of Ligand‐Conjugated NLCs Co‐Loaded With Docetaxel and Quercetin: HPLC Method Development, Pharmacokinetics, and Brain Biodistribution in Wistar Rats for Glioblastoma. Biomedical Chromatography. 2026. doi:10.1002/bmc.70251
BibTeX
@article{Qamar2026,
author = {Qamar, Zufika and Khan, Saif Ahmad and Haider, Farhan and Moonis, Mohammad and Ali, Javed and Baboota, Sanjula and Ali, Asgar},
title = {Intranasal Delivery of Ligand‐Conjugated NLCs Co‐Loaded With Docetaxel and Quercetin: HPLC Method Development, Pharmacokinetics, and Brain Biodistribution in Wistar Rats for Glioblastoma},
journal = {Biomedical Chromatography},
year = {2026},
doi = {10.1002/bmc.70251}
}
EUVIMED